Incidence and risk factors for hyperkalaemia in patients treated for COVID‐19 with nafamostat mesylate
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13646
Abstract: Nafamostat mesylate (NM) is used clinically in combination with antiviral drugs to treat coronavirus disease (COVID‐19). One of the adverse events of NM is hyperkalaemia due to inhibition of the amiloride‐sensitive sodium channels (ENaC). The… read more here.
Keywords: nafamostat mesylate; incidence risk; risk factors; factors hyperkalaemia ... See more keywords
Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
Sign Up to like & getrecommendations! Published in 2020 at "World Journal of Clinical Cases"
DOI: 10.12998/wjcc.v8.i21.5320
Abstract: BACKGROUND Nafamostat mesylate (NM) may prove to be one of the key drugs effective against coronavirus disease 2019 (COVID-19) because of its anti-viral properties and the potential to manage coagulopathy. However, NM tends to increase… read more here.
Keywords: case; nafamostat mesylate; mesylate induced; induced hyperkalemia ... See more keywords
Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
Sign Up to like & getrecommendations! Published in 2020 at "Neural Regeneration Research"
DOI: 10.4103/1673-5374.284981
Abstract: Nafamostat mesylate, an apparent soi-disant panacea of sorts, is widely used to anticoagulate patients undergoing hemodialysis or cardiopulmonary bypass, mitigate the inflammatory response in patients diagnosed with acute pancreatitis, and reverse the coagulopathy of patients… read more here.
Keywords: neuroprotective effects; ischemia nafamostat; nafamostat mesylate; mesylate ... See more keywords